News
-
-
-
-
-
-
-
PRESS RELEASE
TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer
Kineta reopens enrollment for VISTA-101 clinical trial with KVA12123 antibody. Positive results at AACR 2024. TuHURA and Kineta join forces. Acquisition pending. Kintara merger progresses -
-
PRESS RELEASE
Original-Research: ad pepper media International N.V. (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates recommendation on ad pepper media International N.V. to Buy with target price of EUR 2.90, citing Q2 report in line with expectations and optimistic outlook for increased revenue and profitability -